Marion Morton, R.Ph., M.B.A., has more than 25 years of experience in the pharmaceutical industry in marketing, sales, managed care, and customer relations. Her positions have included Global Category Head of Obesity Care at Nestlé Health Sciences, Vice President of Cardiovascular Marketing at Boehringer-Ingelheim, and Vice President of the Transplant Business Franchise for Novartis. She also worked in the Worldwide Medicines Group for Bristol-Myers Squibb.
Matthew Bette is Principal and co-founder of Bette and Cring, a diversified construction management, design-build, and general contracting firm. He has more than 30 years of experience in the construction industry and has been responsible for the successful delivery of over one billion dollars of construction projects. Along with his brother Peter, he helps lead the overall operations of the company.
Walter Borisenok co-founded Fortitech, Inc., in 1986 and served as its President until the sale of the company in November 2012. Fortitech's custom additives blend vitamins, minerals, and other nutrients to help boost the energy and nutritional content of a wide range of food and beverage products. At the time of its sale, Fortitech had 500 employees and operations in nine countries.
Leigh Briscoe-Dwyer, R.Ph., Pharm.D., BCPS, serves on the Board of Directors for the American Society of Health System Pharmacists® (ASHP). She has also served as a New York delegate to the House of Delegates, Chair of the Committee on Nominations, and was a member of the Council on Public Policy, the Practitioner Recognition Committee, and the Advocacy & PAC Advisory Committee and is a past President of the New York State Council of Health-system Pharmacists.
Richard H. Daffner, M.D., F.A.C.R., practiced radiology with Allegheny Radiology Associates and Allegheny General Hospital in Pittsburgh, Pennsylvania, for 30 years. He also taught at several colleges and universities including Temple University School of Medicine and Duke University Medical Center. His list of scholarly accomplishments includes serving as author on 8 textbooks, 27 book chapters, and 169 journal articles.
Paul DerOhannesian II, J.D., is a civil and criminal litigation attorney at the firm DerOhannesian and DerOhannesian in Albany, NY. Prior to joining the firm, Mr. DerOhannesian was an assistant district attorney with the Albany County District Attorney's Office and for 22 years headed the D.A.'s Special Assault Unit. He is the author of a definitive two-volume text, Sexual Assault Trials, Fourth Edition.
Christopher Di Lascia, Pharm.D., is the President, CEO, and co-founder of Transition Patient Services (TPS). He was previously employed with Aventis Pharmaceuticals where he held the position of Global Marketing Director for Lovenox. He began his pharmaceutical industry career as a Hospital Sales Representative with Eli Lilly and Company before leaving to join Schering-Plough as a Managed Care and Government Affairs Manager.
Michael Duteau, R.Ph., is Vice President of Strategic Growth and Operations at Noble Health Services. He previously served as Vice President of Business Development and Strategic Relations at Kinney Drugs, and before that, he was District Pharmacy Supervisor for Eckerd Corporation where he managed 80 pharmacies in Central and Eastern New York State. He is the current president of the New York State Chain Pharmacy Association and a past Chairman (2012-13) of the New York State Board of Pharmacy.
Edward J. Enos, MS, RPh began his career as a pharmacist for Community Health Plan, then transitioned to specialize in computerized patient files, registration, and scheduling and implemented the first Electronic Medical Record (EMR) system in the Capital District. As Director of Operations for Community Care Physicians, Mr. Enos managed 22 primary care, general surgery and imaging locations. Currently, Mr. Enos is a healthcare and physician practice consultant working with clients that include St. Peter’s Health Partners and Hudson Headwaters Health Network.
Susan Learned, Pharm.D., M.D., Ph.D., is the Senior Vice President of Global Clinical Development at Indivior, Inc. Dr. Learned joined Indivior in 2015, after serving as the Vice President, Medicines Development Leader and Head of the Psoriasis and Atopic Dermatitis Care Areas at Stiefel, a GlaxoSmithKline (GSK) company. She spent nearly 20 years at GSK leading various global neurosciences clinical divisions.
James Notaro, R.Ph., Ph.D., is the Founder and President of Clinical Support Services (CSS), Inc., a Buffalo-based provider of medication management solutions. Prior to founding CSS in 1999, he held executive positions with Univera Health Care and was Director of Managed Care Programs/Research & Development with Centrus, an Albany-based prescription benefit management company.
Wallace Pickworth, Ph.D., is a pharmacologist with extensive preclinical and clinical experience. He was with NIH for nearly 30 years from a post-doc position to a tenured staff scientist at the National Institute on Drug Abuse. For the past ten years, Dr. Pickworth has directed clinical research on tobacco and nicotine for Battelle as a Research Leader. He holds licenses to practice pharmacy in two states and serves as an adjunct faculty at two colleges of pharmacy.
Pamela Schweitzer, Pharm.D., retired Rear Admiral (RADM), has more than 25 years of pharmacy, healthcare and health policy experience. RADM Schweitzer retired in 2018 following a four-year term as the Assistant Surgeon General and 10th Chief Pharmacist Officer of the United States Public Health Service (PHS). As Chief Pharmacist Officer (and the first female in this role), she was responsible for providing leadership and coordination of PHS pharmacy programs and professional affairs for the Office of the Surgeon General and the Department of Health & Human Services. She also serves on the Board of Directors of the National Council for Prescription Drug Program Foundation.
Gregory Sciarra, R.PH, MBA is an executive healthcare and pharmaceutical operations leader. He is a regional vice president at Oak Street Health, a network of primary care centers for patients on Medicare and adults over 65. Gregory has vast experience with national retail, healthcare, and finance organizations driving operational and financial improvements focused on generating revenue and building corporate infrastructures and establishing operating controls.
Bill Shields is the retired CEO and current member of the Board of Directors at Advanced Infusion Solutions (AIS), the leading provider of advanced sterile, patient-specific intrathecal pump medications and in-home intravenous infusion including immune globulin therapies. He has a wide range of experience in leadership roles in the healthcare industry. Prior to joining AIS, he served as the President at MTS Medication Technologies, CEO at Artromick International, EVP at Amerisource, Bergen and President of PharMerica.
David Stack is Chairman and CEO of Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company focused on non-opioid medication products for pain management. Mr. Stack has shepherded several therapeutics through clinical development and FDA approval, including the successful commercial launch of the pain control product EXPAREL. In addition to his role with Pacira, Mr. Stack is also a Managing Director at MPM Capital, a venture capital firm focused on life sciences companies.
Scott Terrillion, J.D., is General Counsel at Cara Therapeutics since 2016. He oversees Cara’s legal and compliance functions and serves as company Secretary. Prior to this, he was Vice President and Associate General Counsel at Mesoblast Ltd., a regenerative medicine company. He began his career as Director of Pharmacy at Preferred Care (now MVP Health Care) before spending 17 years at Boehringer-Ingelheim in 1998, where he rose to the position of Vice President and Group General Counsel.
Marc Watrous, R.Ph., Ph.D., is Senior Vice President of Managed Care and Customer Operations for Genentech. He and his team are responsible for the strategic approach and execution of pricing, distribution, reimbursement, and patient support for the company's portfolio. Since joining Genentech in 1997, Marc has also held leadership positions in the R&D Project Management and Portfolio Management units. His first role with Genentech was as a health economist.
As the Principal and Founder of Williamson Biopharma Consulting, Pamela Williamson, RAC, FRAPS, MBA, is an independent consultant for the bio-pharmaceutical industry with more than 30 years of global leadership experience. Ms. Williamson has a strong track record in the successful development and registration of products to treat patients with serious and life-threatening rare diseases. She most recently served as SVP of Global Regulatory Affairs & Patient Safety at Alexion Pharmaceuticals.